Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in HFpEF cardiac structure, fibrosis, and biomarker study
ChiCTR2200060862Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Beijing Hospital. Primary endpoints: Change in extracellular volume by cardiac magnetic resonance imaging after 6 months of treatment and Change in left ventricular mass by cardiac magnetic resonance imaging after 6 months of treatment. Started Jun 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2200060862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060862.